ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pulmonary"

  • Abstract Number: 2674 • ACR Convergence 2025

    Pulmonary ultrasound findings and their relationship with clinical characteristics and myopathy antibodies in a cohort of patients with myositis

    Ana Mora1, Carina Soto-Fajardo2, Jiram Torres-Ruiz3, Diana Gómez-Martín4, Fabian Carranza5, Tabata Cano6, Elena Cervantes Ramírez7, Alejandra Espinosa5, Yatzil Reyna Juárez8 and Carlos Pineda2, 1National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico, Mexico, 2National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico City, Mexico, 3INCMNSZ, Ciudad de México, Mexico, 4INCMNSZ, Mexico city, Federal District, Mexico, 5National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Ciudad de México, Mexico, 6National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Huixquilucan, Mexico, 7National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico, 8Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by muscular and systemic involvement, with interstitial lung disease (ILD) being a challenging problem.…
  • Abstract Number: 1185 • ACR Convergence 2025

    Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15

    Stéphane Mitrovic1, Athénaïs Boucly2, Maryvonnick Carmagnat3, Laurent Savale2, Xavier Jaïs2, Jean-luc Taupin3, Estibaliz Lazaro4, Emilie Berthoux5, nicolas schleinitz6, Maria-Rosa Ghigna7, kedra joanna1, Xavier Mariette8, Céline Roussin9, Pierre Antoine Juge10, Marc Humbert2, Olivier Sitbon2, David Montani2 and Bruno Fautrel11, 1Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, 2Kremlin Bicêtre Hospital, Pulmonology Department, Paris Saclay University, APHP, Le Kremlin Bicêtre, France, 3Saint Louis Hospital, Immunology laboratory, APHP, Paris, France, 4Internal Medicine Department, CHU Bordeaux, Bordeaux, France, 5Saint Joseph Sain Luc Hospital, Internal Medicine Department, Lyon, Lyon, France, 6Aix Marseille university, AP-HM, Marseille, France, 7Marie Lannelongue Hospital, Anatomopathology department, Le Plessis-Robinson, France, 8Université Paris-Saclay, Le Kremlin Bicetre, France, 9Centre Hospitalier Ouest Réunion, Saint Paul, France, 10Hopital Bichat, APHP, Paris, France, 11Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France

    Background/Purpose: Inflammatory lung disease (ILD) in Still’s disease (SD) has recently been described. Pulmonary arterial hypertension (PAH), a rare subtype of pulmonary hypertension (PH), is…
  • Abstract Number: 2438 • ACR Convergence 2025

    SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes

    Ahmad Alomari1, Asim Khanfar2, Miguel Rodriguez3 and Diala Alawneh4, 1UCF- North Florida hospital, Gainesville, FL, 2Rochester General Hospital, Rochester, NY, 3SIMED Rheumatology, Gainesville, FL, 4University of Florida, Gainesville, FL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease linked to significant morbidity, including pulmonary hypertension (PH). While SGLT2 inhibitors are known for cardiovascular…
  • Abstract Number: 0721 • ACR Convergence 2025

    Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Mats Junek1, Sara Choi2, Stephanie Garner3, Saara Rawn4, David Cuthbertson5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Christian Pagnoux11, Philip Seo12, Ulrich Specks13, Kenneth Warrington13, Gerard Cox1, Nader Khalidi14 and Peter Merkel8, 1St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 2Queen's University, Kingston, ON, Canada, 3University of Calgary, Calgary, AB, Canada, 4NOSM School of Medicine, Sudbury, ON, Canada, 5University of South Florida, Tampa, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Moreland Hills, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Johns Hopkins University, Baltimore, MD, 13Mayo Clinic, Rochester, MN, 14McMaster University, Hamilton, ON, Canada

    Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
  • Abstract Number: 2412 • ACR Convergence 2025

    Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis

    Maria Romero Noboa1, Faria Sami2, Almurtada Razok3 and Shahzad Ahmed Sami4, 1University of Alabama at Birmingham, Birmingham, AL, 2The University of Alabama at Birmingham, Birmingham, AL, 3John H Stroger Jr Hospital of Cook County, Chicago, IL, 4DCH Regional Medical Center, Birmingham

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare manifestation of Systemic Lupus Erythematosus (SLE) with increased morbidity and mortality. It has historically been underdiagnosed in…
  • Abstract Number: 0702 • ACR Convergence 2025

    Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.

    Nicola Farina1, Silvia Bellando-Randone2, hilde Bjørkekjær3, David Launay4, Patricia E. Carreira5, paolo airò6, Serena Guiducci7, Dilia Giuggioli8, Gabriela Riemekasten9, carmen-Pilar Simeón Aznar10, Christina Bergmann11, Elise Siegert12, Ivan Castellví13, Lesley Ann Saketkoo14, Jeska de Vries-Bouwstra15, Dr. Philipp Klemm16, ulf Müller-Ladner17, Alexandra Balbir- Gurman18, Vanessa Smith19, Florenzo Iannone20, Luca Idolazzi21, Christopher Denton22, edoardo rosato23, Britta Maurer24, Yannick Allanore25, Yoshiya Tanaka26, elisabetta zanatta27, Marie-Elise Truchetet28, Masataka Kuwana29, Mickaël MARTIN30, Alberto Cauli31, Kamal Solanki32, Francesco Del Galdo33, Ana Maria Gheorghiu34, Branimir Anic35, Gábor Kumánovics36, Gonçalo Boleto37, Kristofer Andréasson38, Simona Rednic39, Lorinda Chung40, susana Oliveira41, marius cadar42, Francesco Paolo Cantatore43, Carolina de Souza Müller44, Vivien Hsu45, Yair Levy46, Gianluca Moroncini47, Jörg Henes48, Andra Balanescu49, and Ellen De Langhe50, , Carlomaurizio Montecucco51, Petros Sfikakis52, Michele Iudici53, Stefan Heitmann54, Madelon Vonk55, Anna-Maria Hoffmann-Vold56, Oliver Distler57, Marco Matucci-Cen58, Cosimo Bruni57, 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, 2University of Florence, Florence, Florence, Italy, 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, 4Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, 7Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, 8Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, 9University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 10Hospital Universitario Vall d'Hebron Passeig, Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Barcelona, Spain, Zaragoza, Spain, 11Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 12Charité University Hospital, Department of Rheumatology, Berlin, Germany, Berlin, Germany, 13Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, 14University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 15Leiden University Medical Center, Leiden, Netherlands, 16Kerckhoff-Klinik Bad Nauheim, Berlin, Germany, 17JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center, Bad Nauheim, Germany, Bad Nauheim, Germany, 18Rambam Health Care Campus, Rheumatology Institute, Haifa, Israel, israel, Israel, 19Ghent University Hospital, Gent, Belgium, 20Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, 21Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, 22University College London, UK, London, United Kingdom, 23Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policlinico Umberto 1-Centro di riferimento regionale per la sclerosi sistemica, Rome, Italy, rome, Italy, 24Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 25Université Paris Cité, Paris, France, 26University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 27Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, 28Bordeaux University Hospital, Bordeaux, France, 29Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 30Poitiers University Hospital, Department of Internal Medicine, Poitiers, France, MIGNALOUX-BEAUVOIR, France, 31Rheumatology Unit, Department of Medicine and Public Health, AOU and University of Cagliari, Cagliari, Italy, 32Waikato Hospital, Hamilton, New Zealand, 33University of Leeds, Leeds, United Kingdom, 34Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, 35University of Zagreb, School of Medicine, University Hospital Center Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, zagreb, Croatia, 36University of Pécs, Department Of Rheumatology And Immunology, Medical Centre, Pecs, Hungary, Pecs, Hungary, 37Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Rheumatology Department, Lisbon, Portugal, Paris, France, 38Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, 39University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Clinica Reumatologie, Cluj-Napoca, Romania, Cluj-Napoca, Romania, 40Stanford University, Stanford, CA, 41Fernando Fonseca Hospital, Department of Medicine IV, Systemic Immunomediated Diseases Unit, Amadora, Portugal, amadora, Portugal, 42Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Rome, Italy, 43University of Foggia, Department of Medical and Surgical Sciences, Rheumatology Unit, Foggia, Italy, foggia, Italy, 44Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil, curitiba, Brazil, 45Rutgers- RWJ Medical School, South Plainfield, NJ, 46Meir Medical Center, Kfar-Saba, Israel, Kefar Sava, Israel, 47Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, 48Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, 49UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, 50University Hospital Leuven, Laboratory of Tissue Homeostasis and Disease, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, 51Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy, 52NKUA - SCHOOL OF MEDICIN, Athens, Greece, 53Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, 54Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199 Stuttgart, Germany, 55Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 56Oslo University Hospital, Oslo, Norway, 57Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 58University San Raffaele Milano, Milano, Italy

    Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…
  • Abstract Number: 2400 • ACR Convergence 2025

    Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing

    Henrik Zachar Langkilde1, Jesper Davidsen2, Stefan Harders3, Stefan Luef4, Susan Kay5, Tine Lottenburger6, Stavros Chrysidis7, Karen Schreiber8, Elisabet Svenungsson9, Sille Fløjborg10, Robin Christensen11 and Anne Voss12, 1Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense, Denmark, 2South Danish Center for Interstitial Lung Diseases (SCILS) and Pulmo-Rheuma Frontline Center (PURE), Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark, Odense, Syddanmark, Denmark, 3Research Unit of Department of Radiology, University of Southern Denmark, Odense University Hospital, Denmark., Odense, Syddanmark, Denmark, 4Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark, Odense, Syddanmark, Denmark, 5Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, 6Department of Rheumatology, Vejle Hospital, Vejle, Denmark, Vejle, Syddanmark, Denmark, 7Department of Rheumatology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark, Esbjerg, Syddanmark, Denmark, 8Danish Center for Expertise in Rheumatology (CeViG), Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, Soenderborg, Syddanmark, Denmark, 9Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 10Systemic Lupus Erythematosus Patient Research Partner, Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, 11Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Hovedstaden, Denmark, 12Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense C, Syddanmark, Denmark

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that potentially affects any organ. Pulmonary diseases (PD) are common in SLE and cover several different…
  • Abstract Number: 0688 • ACR Convergence 2025

    Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study

    Benjamin Chaigne1, Alexandre bense2, Frédérique Aubourg3, Christian AGARD4, Yannick Allanore5, Alice berezne1, Gregory Pugnet6, Eric Hachulla7, Vincent Cottin8, Arnaud Hot8, bertrand Dunogue1, Anuxcy Kanagaratnam2, Sylvain Palat9, Alain Lescoat10, Sabine berthier11, Emmanuel Chatelus12, Sébastien Rivière13, David Launay14, Marie-Elise Truchetet15, Anh-Tuan Dinh-Xuan3 and Luc Mouthon1, 1Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 2AP HP, Paris, France, 3Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5Université Paris Cité, Paris, France, 6CHU, Montpelliers, France, 7CHU, Lilles, France, 8CHU, Lyon, France, 9Limoges, Limoges, France, 10CHU Rennes - University Rennes, Rennes, France, 11CHU, Dijon, France, 12Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, 13AP HP, Parsi, France, 14Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 15Bordeaux University Hospital, Bordeaux, France

    Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
  • Abstract Number: 2259 • ACR Convergence 2025

    Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis

    Saud AlHajeri1, Matthew Major2, Darya S. Jalaledin3, Beatrice Daviault4, Arusa Shah5, Alec Yu6, Sabrina Hoa7, Robert Levy8, Jennifer Wilson1, Charles Poirier4, James Choi6, John Yee6, Océane Landon-Cardinal9, Kun Huang10 and Hyein Kim11, 1UBC, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, Canada, 3Université de Montréal, Saint-Lambert, QC, Canada, 4University of Montreal, Montreal, QC, Canada, 5University of Montreal, Montreal, BC, Canada, 6University of British Columbia, Vancouver, BC, Canada, 7University of Montreal, Brossard, QC, Canada, 8University of British Columbia, Deerfield, IL, 9Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 10University of British Columbia, Vancouver, Surrey, BC, Canada, 11The University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA), ranging from subclinical ILD to advanced fibrosis, and is associated with significant…
  • Abstract Number: 0673 • ACR Convergence 2025

    Association Between Vasoactive-Vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence From a EUSTAR Study

    Nicola Farina1, Silvia Bellando-Randone2, SEBASTIEN SANGES3, hilde Bjørkekjær4, lorenzo tofani5, Marie-Elise Truchetet6, Vanessa Smith7, Andra Balanescu8, Christina Bergmann9, Yannick Allanore10, Philipp Klemm11, simona Truglia12, Luca Idolazzi13, Christopher Denton14, Roberta Foti15, anna Wojteczek16, Emmanuel Chatelus17, Madelon Vonk18, Serena Guiducci19, David Launay20, Eric Hachulla21, Jeska de Vries-Bouwstra22, Anna-Maria Hoffmann-Vold23, Marco Matucci-Cerinic24, Oliver Distler25 and Cosimo Bruni26, 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, 2University of Florence, Florence, Florence, Italy, 3Medecine Interne CHRU Lille, Lille, France, 4Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, 5Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, 6Bordeaux University Hospital, Bordeaux, France, 7Ghent University Hospital, Gent, Belgium, 8UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, 9Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 10Université Paris Cité, Paris, France, 11Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, 12Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy, rome, Italy, 13Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, 14University College London, UK, London, United Kingdom, 15Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy, Catania, Italy, 16Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdańsk, University Clinical Centre, Gdańsk, Poland, Gdańsk, Poland, 17Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, 18Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 19Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, 20Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 21University of Lille, LILLE, France, 22Leiden University Medical Center, Leiden, Netherlands, 23Oslo University Hospital, Oslo, Norway, 24University San Raffaele Milano, Milano, Milan, Italy, 25Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 26University of Zurich, Zurich, Switzerland

    Background/Purpose: Vasoactive-vasodilating drugs (VVD) are the cornerstone of the treatment of pulmonary arterial hypertension (PAH), a form of precapillary pulmonary hypertension (pPH) that represents a…
  • Abstract Number: 2258 • ACR Convergence 2025

    Clinical Associations of Pulmonary Hypertension in RA Patients with and without Interstitial Lung Disease

    Sanjita Gowda1, Yuri Matusov2, Amara Seng1, Nunzio Bottini3 and Jon Giles4, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, 3Cedars Sinai Medical Center, Beverly Hills, CA, 4Cedars Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Pulmonary diseases are contributors to the morbidity and mortality of RA. Despite the recent surge in studies of RA-associated interstitial lung disease (RA-ILD), there…
  • Abstract Number: 0621 • ACR Convergence 2025

    Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort

    Luis Javier Cajas Santana1, Sebastián Molina-Ríos1, Lucia Hernández2, Romina Nieto3, Gricel Maita Romero4, Nidia Noemí Merás5, Veronica Gabriela Savio6, Veronica Saurit7, Valeria Arturi8, Boris Kisluk9, Inés Verónica Bellomio10, Mario Eduardo Kerzberg11, Nicolas Perez12, Cecilia Pisoni13, Vicente Juarez14, Joaquín Martinez Serventi15, Nélzio Silva16, ODIRLEI MONTICIELO17, Mariana Souza Pessoa de Luna18, Laíssa Cristina Alves Alvino19, Eduardo Borba20, Luciana Parente Costa Seguro20, Edgard dos Reis-Neto21, Iris Guerra Herrera22, Milena Mimica23, Gustavo Aroca Martínez24, Valentina Pérez jiménez25, Carlos Alberto Cañas26, Gerardo Quintana-Lopez27, Carlos Toro-Gutierrez28, Rafael Ignacio López Martínez29, MIGUEL SAAVEDRA30, Margarita Portela Hernández31, Hilda Fragoso-Loyo32, Luis H Silveira33, Yelitza Gonzalez Bello34, Carlos Abud-Mendoza35, Jorge Antonio Esquivel Valerio36, Patricia Langjahr37, Astrid Paats38, Claudia S. Mora-Trujillo39, Victor Pimentel-Quiroz40, Carlos Bedia41, Teresandris Polanco Mora42, Martin Rebella43, Alvaro Danza44, Federico Zazzetti45, Ashley Orillion46, Guillermo Pons-Estel3 and Graciela Alarcón47, 1Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 3Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina;, Córdoba, Argentina, 6Universidad Nacional de Córdoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 8Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, 9Sanatorio Británico, Rosario, Argentina, Rosario, Argentina, 10Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, 11Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, 12Instituto de Investigaciones Médicas Dr. Alfredo Lanari, Buenos Aires, Argentina, 13CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, 14Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 15Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, 16Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, 17Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 18Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, 19Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, 20Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 21Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, 22Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 23Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 24Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, 25Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, 26Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 27Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 28Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 29Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 30Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, 31Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 32Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 33Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 34Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, 35Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, 36Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 37Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, San Lorenzo, Paraguay, 38Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, 39Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, 40Universidad Científica del Sur, San Isidro, Peru, 41Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima, Peru, Lima, Peru, 42Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 43Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 44Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, 45Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 46Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 47The University of Alabama at Birmingham, Oakland, CA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disease. Pleuropulmonary (PP) manifestations, including pleural effusion (PE), interstitial lung disease (ILD), pulmonary hypertension (PH), shrinking…
  • Abstract Number: 2249 • ACR Convergence 2025

    Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies

    Marina Pavía-Pascual1, Marina Sánchez-Lucas2, Camille Bourgeois3, Maria Teresa Schiaffino Garcia-Villanova4, Julia Martínez Barrio5, Juan Molina-Collada6, Esther Chamorro De Vega7, José María álvaro-Gracia álvaro8 and Isabel Castrejón Fernández9, 1Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, 2Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain, 3Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, 4Department of Immunology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, 5Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, 6Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, 7Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, 8Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Department of Medicine, Complutense University, Madrid, Spain., Madrid, Madrid, Spain, 9MD, PhD, Madrid, Madrid, Spain

    Background/Purpose: Interstitial lung disease (ILD) is the second leading cause of mortality in rheumatoid arthritis (RA) but often goes underdiagnosed due to its variable clinical…
  • Abstract Number: 0622 • ACR Convergence 2025

    Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes

    Malvika Gupta1 and Chander Raman2, 1Mayo Clinic, Rochester MN, Rochester, MN, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Shrinking Lung Syndrome (SLS) is a rare pulmonary complication of systemic lupus erythematosus (SLE), characterized by unexplained dyspnea, pleuritic chest pain, loss of lung…
  • Abstract Number: 2141 • ACR Convergence 2025

    Treatment of Refractory Still’s/Systemic Juvenile Idiopathic Arthritis Lung Disease with the bi-specific IL-1Beta/IL-18 neutralizing antibody MAS825

    Hallie Carol1, Monica Manglani2, Abass Noor2, Edward Behrens3, Jon Burnham4, Jessica Lee2, Jordan Moreno2, Alexandra Chop5, Kader Cetin Gedik6, Catherine Poholek7, Ginger Janow8, Lindsay Waqar-Cowles1 and Scott Canna1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, 3CHOP, West Chester, PA, 4Children's Hospital of Philadelphia, Bryn Mawr, PA, 5UPMC, Pittsburgh, PA, 6UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, 7University of Pittsburgh, Pittsburgh, PA, 8Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ

    Background/Purpose: Despite major advances in the understanding, diagnosis, and treatment of Still’s disease (including Systemic Juvenile Idiopathic Arthritis, sJIA), many patients experience a refractory course.…
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology